论文部分内容阅读
全身应用rIL-2治疗癌症患者,尽管具有明显的抗肿瘤作用,但由于严重的毒副作用,其疗效受到一定限制。为探讨一种避免全身毒副反应的IL-2免疫治疗方法,以逆转录病毒(PLJ)为载体,将IL-2cDNA转染小鼠胸腺瘤EL_4细胞,用IL-2依赖细胞株CTLL2筛选一株高分泌IL-2(500IU/ml/24h/5 ×10~5细胞)细胞株(EL_(4P)IL-2),另外以同样方法构建不分泌IL-2的EL_(4P)细胞株为对照株,体外大量扩增这两种细胞株。将多种剂量的EL_(4P)IL-2或EL_(4P)细胞分别皮下接种于C57BL/ 6小鼠,观察诱发肿瘤的情况,结果发现,小鼠对EL_(4P)IL-
Systemic application of rIL-2 in the treatment of cancer patients, despite having a significant anti-tumor effect, due to severe toxic side effects, its efficacy is limited. To explore a method of IL-2 immunotherapy for avoiding systemic toxicities and side effects, IL-2 cDNA was transfected into mouse thymoma EL4 cells using retroviral vector (PLJ) and screened with IL-2 dependent cell line CTLL2. IL-2 (500IU/ml/24h/5 × 10~5 cells) cell line (EL_(4P)IL-2) was secreted in plant height, and EL_(4P) cell line that did not secrete IL-2 was constructed in the same manner as For control strains, these two cell lines were extensively expanded in vitro. Various doses of EL_(4P)IL-2 or EL_(4P) cells were subcutaneously inoculated into C57BL/6 mice, and the induced tumors were observed. The results showed that mice were exposed to EL_(4P)IL-